DEFSEC Technologies (NASDAQ:DFSC – Get Free Report) and Mainz Biomed (NASDAQ:MYNZ – Get Free Report) are both small-cap industrials companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership and valuation.
Volatility & Risk
DEFSEC Technologies has a beta of 2.82, suggesting that its share price is 182% more volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings for DEFSEC Technologies and Mainz Biomed, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DEFSEC Technologies | 1 | 0 | 0 | 0 | 1.00 |
| Mainz Biomed | 1 | 1 | 0 | 0 | 1.50 |
Earnings & Valuation
This table compares DEFSEC Technologies and Mainz Biomed”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DEFSEC Technologies | $3.53 million | 0.43 | -$6.88 million | ($4.62) | -0.16 |
| Mainz Biomed | $659,935.00 | 14.00 | -$21.65 million | ($65.60) | -0.02 |
DEFSEC Technologies has higher revenue and earnings than Mainz Biomed. DEFSEC Technologies is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
21.4% of DEFSEC Technologies shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares DEFSEC Technologies and Mainz Biomed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DEFSEC Technologies | -120.97% | -144.66% | -82.13% |
| Mainz Biomed | N/A | N/A | N/A |
Summary
Mainz Biomed beats DEFSEC Technologies on 7 of the 12 factors compared between the two stocks.
About DEFSEC Technologies
DEFSEC develops and commercializes breakthrough next-generation tactical systems for military and security forces. The Company’s current portfolio of offerings includes digitization of tactical forces for real-time shared situational awareness and targeting information from any source (including drones) streamed directly to users’ smart devices and weapons. Other DEFSEC products include countermeasures against threats such as electronic detection, lasers and drones. These systems can operate stand-alone or integrate seamlessly with OEM products and battlefield management systems, and all come integrated with TAK. The Company also has a new proprietary non-lethal product line branded PARA OPSTM with applications across all segments of the non-lethal market, including law enforcement. The Company is headquartered in Ottawa, Canada, with representative offices in London, UK and Abu Dhabi, UAE.
About Mainz Biomed
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.
Receive News & Ratings for DEFSEC Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DEFSEC Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
